Form 4: Myriad Genetics Executive Acquires Shares Following Performance-Based Vesting

Mark Verratti, Chief Commercial Officer of Myriad Genetics, acquired 12,758 shares of common stock on February 7, 2025, following the vesting of performance-based restricted stock units (PSUs).

Summary

• On February 7, 2025, Mark Verratti, the Chief Commercial Officer of Myriad Genetics, acquired 12,758 shares of common stock.
• This acquisition resulted from the vesting of performance-based restricted stock units (PSUs) that were initially granted on March 22, 2022.
• The Compensation and Human Capital Committee of the Company's Board of Directors determined the final award amount based on the accomplishment of applicable performance metrics.
• Each PSU represents a contingent right to receive one share of the Company's common stock and vests on March 22, 2025.
• Following the transaction, Verratti directly owns 302,035 shares of Myriad Genetics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs suggests that the company has met certain performance targets, which is a positive indicator. The executive's increased ownership also signals confidence in the company's future.

Positives

• The vesting of performance-based restricted stock units suggests that the company has met certain performance metrics, which could be viewed positively by investors.
• The acquisition of shares by a high-ranking executive demonstrates confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Executive stock ownership is a common practice in publicly traded companies and is often used to align management's interests with those of shareholders. The vesting of performance-based equity indicates that the company has achieved certain pre-defined goals.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards, such as PSUs, to incentivize executives to achieve specific financial or operational targets.
• The vesting of these awards is typically tied to metrics such as revenue growth, profitability, or stock price appreciation.
• Companies like Illumina, Thermo Fisher Scientific, and Danaher also utilize similar compensation strategies to align executive incentives with shareholder value creation.

Stakeholder Impact

• Shareholders may view the vesting of performance-based equity as a positive sign, indicating that management is incentivized to achieve company goals.
• Employees may be motivated by the company's achievement of performance targets.
• The transaction has no immediate impact on customers, suppliers, or creditors.

Key Dates